title: Severe persistent asthma in adults. The rise of omalizumab.
authors.affiliation: Wyckoff Heights Medical Center, Brooklyn, NY, USA.
authors.forename: Lorraine A
authors.initials: LA
authors.lastname: Sanassi
mesh_terms: D000293:Adolescent; D000328:Adult; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001249:Asthma / Q000175:diagnosis* / Q000188:drug therapy* / Q000503:physiopathology; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D008875:Middle Aged; D000069444:Omalizumab; D017410:Practice Guidelines as Topic; D012720:Severity of Illness Index; D014481:United States; D055815:Young Adult
chemical_list: D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab